Stockreport

Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019

Oragenics Inc.  (OGEN) 
NASDAQ:AMEX Investor Relations: ir.oragenics.com
PDF TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American:OGEN) (“Oragenics”), a leader in the development of novel antibiotics against infectious diseases and ef [Read more]